MBX Biosciences, Inc. Common Stock - Asset Resilience Ratio
MBX Biosciences, Inc. Common Stock (MBX) has an Asset Resilience Ratio of 87.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MBX Biosciences, Inc. Common Stock (MBX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how MBX Biosciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MBX Biosciences, Inc. Common Stock (MBX) total assets.
Liquid Assets Composition Over Time
This chart breaks down MBX Biosciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MBX Biosciences, Inc. Common Stock (MBX) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $394.76 Million | 87.2% |
| Total Liquid Assets | $394.76 Million | 87.20% |
Asset Resilience Insights
- Very High Liquidity: MBX Biosciences, Inc. Common Stock maintains exceptional liquid asset reserves at 87.20% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MBX Biosciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MBX Biosciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for MBX Biosciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.48% | $298.42 Million | $385.14 Million | -1.76pp |
| 2024-12-31 | 79.24% | $212.80 Million | $268.54 Million | +19.67pp |
| 2023-12-31 | 59.58% | $50.15 Million | $84.18 Million | +19.11pp |
| 2022-12-31 | 40.47% | $18.25 Million | $45.09 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more